Exelixis Comprehensive Income 2010-2024 | EXEL

Exelixis comprehensive income for the quarter ending September 30, 2024 was $0.004B, a 128.23% decline year-over-year.

  • Exelixis comprehensive income for 2023 was $-0.004B, a 74.18% decline from 2022.
  • Exelixis comprehensive income for 2022 was $-0.015B, a 1815.7% increase from 2021.
  • Exelixis comprehensive income for 2021 was $-0.001B, a 116.93% decline from 2020.

Exelixis Comprehensive Income 2010-2024 | EXEL

  • Exelixis comprehensive income for 2023 was $-0.004B, a 74.18% decline from 2022.
  • Exelixis comprehensive income for 2022 was $-0.015B, a 1815.7% increase from 2021.
  • Exelixis comprehensive income for 2021 was $-0.001B, a 116.93% decline from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$173B
Vertex Pharmaceuticals (VRTX)$129.2B
Bristol Myers Squibb (BMY)$121.3B
Gilead Sciences (GILD)$120.8B
CSL (CSLLY)$91.5B
Regeneron Pharmaceuticals (REGN)$90.7B
GSK (GSK)$75.3B
Alnylam Pharmaceuticals (ALNY)$36.1B
Argenex SE (ARGX)$35.2B
BioNTech SE (BNTX)$26.1B
Biogen (BIIB)$25.1B
Illumina (ILMN)$24B
BeiGene (BGNE)$20B
Moderna (MRNA)$16.5B
Incyte (INCY)$15.7B
Genmab (GMAB)$15.4B
Vaxcyte (PCVX)$12.9B
Insmed (INSM)$12.8B
BioMarin Pharmaceutical (BMRN)$12.6B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.3B
Revolution Medicines (RVMD)$10.2B
QIAGEN (QGEN)$10.1B
Intra-Cellular Therapies (ITCI)$9.7B
Exact Sciences (EXAS)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
Roivant Sciences (ROIV)$8.7B
Repligen (RGEN)$7.8B
Ascendis Pharma (ASND)$7.8B
Halozyme Therapeutics (HALO)$7.8B